












































Inhibitors of the renin–
angiotensin–aldosterone
system and COVID-19 in
critically ill elderly patients
Severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), the coronavirus that causes
COVID-19, uses the membrane-bound form of
the aminopeptidase angiotensin-converting en-
zyme 2 (ACE2) to enter cells. Since ACE2 is
centrally involved in the regulation of the
renin–angiotensin–aldosterone system (RAAS),
it has been speculated that RAAS inhibitors in-
fluence clinical courses. Mehta et al.1 found no
association between use of RAAS inhibitors
and likelihood of COVID-19 testing positivity in
18 472 patients. Reynolds et al. performed a
study based on data from electronic health
records (5894 COVID-19 cases), where a
Bayesian analysis showed no positive associ-
ation of RAAS inhibitors with either a positive
test result or severe illness.2 Mancia et al.3 also
found no evidence in a population-based case-
control study (6272 case-patients) for RAAS
inhibitors to affect the risk of contracting
COVID-19.
However, although these retrospective stud-
ies report essential data, they are of limited use
to inform on elderly, comorbid and severely ill
patients, who represent the most vulnerable
group of patients affected by COVID-19 and
are also most likely treated with RAAS inhibi-
tors within the general population. To investi-
gate special clinical features in COVID-19, the
COVIP study (Very old intensive care patients,
VIP network; NCT04321265) is ongoing.
COVIP prospectively includes patients equal to
or above 70 years of age with proven COVID-
19 who are admitted to an intensive care unit
(ICU). A total of 244 ICUs in 38 countries are
registered to participate in COVIP. The primary
endpoint is death after 30 days. Inclusion crite-
ria are (i) age >_70 years, (ii) ICU admission, and
(iii) infection with SARS-CoV-2. Furthermore, a
follow-up will be performed after 3 months to
assess death and quality of life. The prospective
design aims to create high-quality data about
risk factors, comorbidities, pre-existing frailty,
ICU-treatment including treatment limitations,
and the use of experimental drugs in this critic-
ally ill patient collective of elderly patients. An
interim analysis was performed on 7th of May
with respect to RAAS inhibitor use.
In total, 324 patients were evaluated
(Table 1): 157 (48%) were on RAAS inhibitors,
62 (19%) on angiotensin-converting enzyme
inhibitors (ACE-I), and 95 (29%) on angiotensin
II receptor blockers (ARB) before disease
onset. Overall ICU mortality was 45% and was
similar between patients with and without
previous ARB (45% vs. 45%; P = 0.98), but
lower in patients with previous ACE-I (31% vs.
49%; P = 0.01). A propensity for being on ACE-I
was calculated using logistic regression, the
covariates were age, body mass index, sex, se-
quential organ failure assessment (SOFA)
score, as well as existing comorbidities of
chronic heart failure, ischaemic heart disease,
renal insufficiency, chronic pulmonary disease,
arterial hypertension, and diabetes mellitus
(Table 1). The primary endpoint was ICU mor-
tality. Both univariable (Model 1) and multivari-
able (Model 2, propensity score correction)
logistic regression models were built to evalu-
ate associations with the primary endpoint.
Odds ratios (OR, Model 1, Table 1) and
adjusted ORs (aOR, Model 2) with respective
95% confidence intervals (CIs) were calculated.
The univariate association of previous ACE-I
with lower mortality (OR 0.46, 95% CI 0.26–
0.84; P = 0.01; Table 1) remained statistically sig-
nificant after propensity score adjustment (aOR
0.32, 95% CI 0.15–0.67; P = 0.002).
In conclusion, in a prospective study of elder-
ly, critically ill and comorbid patients, we do
find a beneficial association of previous ACE-I
use with ICU survival. The current data con-
firms the notion that there is either a positive
or no effect of RAAS inhibitor use. In addition,
our data support the current view that continu-
ation of RAAS inhibitor use should be
....................................................................................................................................................................................................................
Table 1 Patient characteristics in all patients and in survivors and non-survivors, respectively
All patients Survivors Non-survivors P-values OR (95% CI)
(n 5 324) (n 5 177) (n 5 147)
Age 75 (70–93) 74 (70–93) 77 (70–88) <0.0001* —
BMI 26.8 (18.3–51.4) 26.9 (18.3–41.5) 26.5 (18.3–51.4) 0.65 —
Male/female sex 224/100 (69/31) 116/61 (52/61) 108/39 (48/39) 0.12 1.46 (0.90–2.35)
SOFA score 6 (1–17) 5 (2–13) 7 (1–17) <0.0001* —
Chronic heart failure 45 (14.1) 20 (11.5) 25 (17.2) 0.14 1.60 (0.85–3.03)
Ischaemic heart disease 63 (19.7) 31 (17.8) 32 (22.1) 0.40 1.31 (0.75–2.27)
Renal insufficiency 49 (15.2) 18 (10.2) 31 (21.1) 0.007* 2.35 (1.25–4.40)*
Pulmonary disease 82 (25.5) 41 (23.3) 41 (28.3) 0.31 1.30 (0.79–2.15)
Arterial hypertension 211 (65.1) 115 (65.0) 96 (65.3) 0.95 1.02 (0.64–1.61)
Diabetes mellitus 95 (29.4) 48 (27.1) 47 (32.2) 0.32 1.28 (0.79–2.06)
ACE-I 62 (19.1) 43 (24.3) 19 (12.9) 0.01* 0.46 (0.26–0.84)*
ARB 95 (29.3) 52 (29.4) 43 (29.3) 0.98 0.99 (0.62–1.61)
All continuous variables were non-normally distributed, are presented as median (range) and were compared using Mann–Whitney U tests; categorical variables are presented
as n (%) and were compared using v2 tests; P-values and Cochran–Mantel–Haenszel estimates are reported, presented as odds ratios (ORs) with 95% confidence intervals
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..recommended.4 In summary, this is the first
prospective multinational study that demon-
strates beneficial associations of ACE-I in high-
risk COVID-19 patients and thus impact on
daily practice. However, further research evalu-
ating potential causality is warranted.
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Switzerland; 12Department of Intensive Care
Medicine, Inselspital, Universitätsspital,
University of Bern, Freiburgstrasse 18, 3010
Bern, Switzerland; 13Department of Intensive
Care Medicine, University Medical Center,
University Utrecht, Heidelberglaan 100, 3584
CX Utrecht, the Netherlands; 14Assistance
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